MedTrace Logo

A Study in Healthy People to Test How Combining BI 1467335 and Tyramine Affects Blood Pressure

NCT03979820 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 53

Last updated 2021-06-04

Study results available
· View outcomes & findings →

Summary

The main objective of the study is investigate the effect of escalating doses of oral tyramine on systolic blood pressure (SBP) at baseline and following an oral treatment with BI 1467335 up to 39 days at a low or high dose once daily compared to placebo and phenelzine (Nardil®) as positive control.

Conditions

  • Healthy

Interventions

DRUG

BI 1467335

Film-coated tablet

DRUG

Placebo

Film-coated tablet

DRUG

Phenelzine sulfate

Film-coated tablet

DRUG

Tyramine

Capsules

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-07-31
Primary Completion
2020-04-08
Completion
2020-04-08

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03979820 on ClinicalTrials.gov